Market Research Report
Global Testicular Cancer Drugs Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||294980|
|Published||Content info||111 Pages
Delivery time: 1-2 business days
|Global Testicular Cancer Drugs Market 2019-2023|
|Published: January 17, 2019||Content info: 111 Pages||
The availability of combination therapies for the treatment of testicular cancer will drive market growth during the forecast period. Combined drug therapy is more effective compared with single-drug therapy. Researchers are focused on the development of new combination therapies because of their effectiveness in treating testicular cancer. Technavio's analysts have predicted that the testicular cancer drugs market will register a CAGR of over 4%by 2023.
There has been an increase in the prevalence of testicular cancer globally. Estrogenic activity results in hormonal disruption and is responsible for the gradually increasing incidence of testicular cancer. In 2015, in the US, 17.52% of the total population of men were living with testicular cancer.
The market has alternative treatment options for testicular cancer, including radiation therapy and surgery. Surgery is the first-line treatment in most cases and is generally curative. Radiation therapy is a method in which high-energy X-rays are used to destroy cancer cells. These alternative treatment methods may limit the consumption of drugs and pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the testicular cancer drugs market during the 2019-2023, view our report.view our report.
The market appears to be fairly concentrated and with the presence of few countries. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.